Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6057
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SYS6057 is a recombinant protein vaccine candidate developed by CSPC Pharmaceutical Group for the prevention of Respiratory Syncytial Virus (RSV) infection. Developed by the group's R&D subsidiary, ZhongQi Pharmaceutical Technology, the vaccine utilizes recombinant technology to express viral antigens intended to stimulate a protective immune response. In August 2023, the company received approval from the China National Medical Products Administration (NMPA) to initiate clinical trials. The program aims to address the significant disease burden of RSV in vulnerable populations, including infants and older adults.
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on SYS6057.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6057.